2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Gene Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric, Animal Model
PAPER

3186 Single-cell genotyping and long-read RNA sequencing identifies splicing dysregulation relevant to U2AF1S34 mutant clonal hematopoiesis in telomere biology disorders

Nickolas Steinauer, M.D., Ph.D., Mariela Cortés-López, Ph.D.2, Saravanan Ganesan, PhD3, Terra Lasho, PhD4, Christy Finke, BS5, Jenna Fernandez, Ph.D.6, Rachel Reither7, Abhishek Avinash Mangaonkar, MBBS8, Dan Avi Landau, MD, PhD9, Mrinal M. Patnaik, MD, MBBS10, Alejandro Ferrer, PhD11
1 Mayo Clinic, Rochester, Minnesota, United States
2 Helmholtz Munich, Munich, Germany
3 Weill Cornell Medical College, New york, New York, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Weill Cornell Medical College, New york, New York, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States

Background: Somatic missense mutations of the splicing factor U2-associated factor 1 (U2AF1) occur in both the first (S34) and second (Q157) zinc fingers and are frequently seen in age-related clonal hematopoiesis (CH), increasing the risk of further evolution to clonal cytopenia (CCUS) or myeloid malignancy (MDS/AML). Interestingly, U2AF1-mutant CH is frequently observed in younger patients with telomere biology disorders (TBD), a syndrome characterized by pathogenic germline variants (PGV) in telomere maintenance genes (TERT, TERC, RTEL1, etc.), bone marrow failure, pulmonary and liver fibrosis, and an elevated risk of developing MDS and AML. In this context, U2AF1 mutations almost always involve the first zinc finger at the S34 hotspot, though the reasons for this selectivity remain unclear. We hypothesized that U2AF1-mutant CH relies on mis-spliced transcripts specific to the U2AF1S34 variant to overcome the fitness constraints inherent to TBD.

Methods: To further explore this hypothesis, we utilized 10X 5’ scRNA-Seq with targeted genotyping of transcriptomes and single-cell long-read RNA-Seq (“GoT-Splice”) to profile the short-read and long-read transcriptome, along with U2AF1S34 genotype, at a single-cell level. We applied this method to magnetic bead enriched CD34+ bone marrow mononuclear cells (BMMC) collected from three patients (ages 28, 32, and 71) with TBD (carrying 2 TERT and 1 TERC PGVs) and concurrent U2AF1S34-mutant CH. Single cell derived cDNA was amplified with primers flanking the U2AF1S34 region and sequenced along with 5’ scRNA-Seq libraries. scRNA-Seq reads were quantified and analyzed with cellranger and Seurat, respectively. Genotyping amplicon reads were processed with the IronThrone pipeline (Cortés-López, M. et al., Cell Stem Cell 2023). Long-read RNA-Seq libraries were prepared and sequenced with both ONT (n=2) and PacBio (n=1) platforms. IsoQuant (v3.13.0) was used to quantify long reads against a de novo transcript annotation that was derived from the largest sample’s long-read library compared against Gencode v49. The R package “isopod” was used to test for differential transcript usage between mutant and wildtype cells, using 10,000 permutations.

Results: After quality control filtering and integration of scRNA-Seq datasets, we obtained data for 29,439 BMMCs. GoT-derived U2AF1 variant allele fractions (VAF) correlated closely with VAFs derived from clinical sequencing panels (10% vs 19%, 20% vs 18%, and 11% vs 8%). Despite CD34+ BMMC enrichment, we observed a paucity of primitive hematopoietic stem cells (HSCs) (1.4%), possibly reflecting the state of bone marrow failure in this cohort, although we observed U2AF1-mutant cells within myeloid and lymphoid compartments across all three patients, indicating an HSC cell of origin. Long-read sequencing identified 52,245 transcripts that were expressed at a count of ≥ 5 in ≥ 15 cells, and of these, 41% were novel to the Gencode v49 annotation. We assessed cell type-specific changes in transcript usage between U2AF1-mutant and wildtype cells, and found that CD14+ monocytes, CD14+/CD16+ monocytes, and B cells exhibited the greatest number of differentially utilized transcripts (DTU). Notably, within U2AF1-mutant CD14+ monocytes, there was a significant increase in the usage of ENST00000877621.1, which encodes macroH2A1.2, a splice isoform of the histone variant macroH2A1 that is enriched in telomeric regions and mediates the alternative lengthening of telomeres (ALT) pathway (Kim, J. et al., Nat Struct Mol Biol 2019). This splice variant has been previously linked to the U2AF1S34 mutation (Kim, S. et al., Cell Reports 2021), and through analysis of a publicly available MDS RNA-Seq dataset (GSE128429), we verified that this splice variant is present in U2AF1S34 while absent in U2AF1Q157 variant MDS.

Conclusion: Using single cell genotyping, scRNA-Seq, and long-read sequencing, we profiled the cell type-specific splicing changes present in U2AF1-mutant CH, in the context of TBD. We identified an enrichment of U2AF1S34-dysregulated splicing in B cell, monocyte and promonocytic cell types, including relative upregulation of the macroH2A1.2 isoform that promotes the ALT pathway and may represent an adaptive splicing change in the context of TBD.

Nickolas Steinauer, M.D., Ph.D.: No relevant conflicts of interest to declare.